
|Videos|February 8, 2016
Will Biosimilars Reduce Specialty Drug Spending?
Author(s)Davy James, Managing Editor
National Association of Specialty Pharmacy (NASP) Executive Director James E. Smeeding, RPh, MBA, discusses the potential of biosimilars to reduce the cost burden of specialty pharmaceuticals.
Advertisement
National Association of Specialty Pharmacy (NASP) Executive Director James E. Smeeding, RPh, MBA, discusses the potential of biosimilars to reduce the cost burden of specialty pharmaceuticals.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Sotatercept Demonstrates Significant Reduction in Morbidity and Mortality Across Broader PAH Risk Groups
2
SGLT2 Inhibitors Linked to Lower Atrial Fibrillation Risk, Recurrence
3
Integrating Combination Therapies for Type 2 Diabetes and CKD
4
Evolving Mortality Trends in Heart Failure and Vascular Disease: The Critical Role of Pharmacists in Addressing Cardiovascular Risk
5












































































































































































































